Judy Dering

5.5k total citations · 1 hit paper
41 papers, 3.6k citations indexed

About

Judy Dering is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Judy Dering has authored 41 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 22 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Judy Dering's work include HER2/EGFR in Cancer Research (10 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Ovarian cancer diagnosis and treatment (6 papers). Judy Dering is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Ovarian cancer diagnosis and treatment (6 papers). Judy Dering collaborates with scholars based in United States, United Kingdom and Canada. Judy Dering's co-authors include Dennis J. Slamon, Richard S. Finn, Charles Ginther, Amrita Desai, Ondrej Kalous, Dylan Conklin, Mohammad Atefi, David J. Cohen, Camilla Fowst and Isan Chen and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Judy Dering

41 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

2009 1.0k citations Richard S. Finn, Judy Dering et al. Breast Cancer Research profile →

Peers

Countries citing papers authored by Judy Dering

Since Specialization

Citations

This map shows the geographic impact of Judy Dering's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy Dering with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy Dering more than expected).

Fields of papers citing papers by Judy Dering

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy Dering. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy Dering. The network helps show where Judy Dering may publish in the future.

Co-authorship network of co-authors of Judy Dering

This figure shows the co-authorship network connecting the top 25 collaborators of Judy Dering. A scholar is included among the top collaborators of Judy Dering based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy Dering. Judy Dering is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy	PLoS ONE	Jason J. Zoeller, Michael F. Press et al.	8
2	Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures	Gynecologic Oncology	Boris Winterhoff, Habib Hamidi et al.	40
3	Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer	JNCI Journal of the National Cancer Institute	Gottfried E. Konecny, Chen Wang et al.	267
4	Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer	Clinical Cancer Research	Richard S. Finn, Michael F. Press et al.	20
5	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth	Molecular Cancer Therapeutics	Edward B. Garon, Richard S. Finn et al.	56
6	A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer	Clinical Cancer Research	Dong‐Joo Cheon, Yunguang Tong et al.	265
7	AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53	Breast Cancer Research and Treatment	Ondrej Kalous, Dylan Conklin et al.	22
8	Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro	Hepatology	Richard S. Finn, Alexey Aleshin et al.	43
9	POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer	Gynecologic Oncology	Beth Y. Karlan, Judy Dering et al.	75
10	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer	Journal of Thoracic Oncology	Edward B. Garon, Richard J. Pietras et al.	47
11	Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro	Cancer Research	Richard S. Finn, Danyun Zhao et al.	13
12	Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines	Molecular Cancer Therapeutics	Edward B. Garon, Richard S. Finn et al.	49
13	Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer	Journal of Clinical Oncology	Richard S. Finn, Michael F. Press et al.	144
14	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro breakdown →	Breast Cancer Research	Richard S. Finn, Judy Dering et al.	1044
15	Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer	Breast Cancer Research and Treatment	Brenda Cohen, Mamiko Shimizu et al.	131
16	Activity of the multikinase inhibitor dasatinib against ovarian cancer cells	British Journal of Cancer	Gottfried E. Konecny, Rickard Glas et al.	81
17	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer	Journal of Clinical Oncology	Angelo Di Leo, Henry Gómez et al.	345
18	Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells	British Journal of Cancer	Gottfried E. Konecny, Natarajan Venkatesan et al.	92
19	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro	Breast Cancer Research and Treatment	Richard S. Finn, Judy Dering et al.	330
20	HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells	Breast Cancer Research	Cindy Wilson, Elaina Cajulis et al.	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact